Defining immunological mechanisms of serovar cross-reactivity to develop broad spectrum protective vaccines for typhoidal and non-typhoidal Salmonella infections in humans

定义血清型交叉反应的免疫学机制,以开发针对人类伤寒和非伤寒沙门氏菌感染的广谱保护性疫苗

基本信息

  • 批准号:
    10584484
  • 负责人:
  • 金额:
    $ 90.67万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2019
  • 资助国家:
    美国
  • 起止时间:
    2019-03-15 至 2025-02-28
  • 项目状态:
    未结题

项目摘要

ABSTRACT (CETR RP5, Sztein, PL) Infection with Salmonella spp. due to ingestion of contaminated food and water, including typhoidal (caused largely by S. Typhi (ST) and S. Paratyphi A (PA)), as well as non-typhoidal (NTS) and invasive NTS (iNTS) infections are major public health concerns in many areas of the World, including in the U.S. where NTS causes 1.2 million illnesses annually. The rapid increase in multidrug resistance (MDR) and the lack of vaccines against PA, NTS or iNTS have added a new sense of urgency for the development of vaccines against these pathogens, and ideally broad-spectrum vaccines. One of the major obstacles in developing vaccines against Salmonella spp. is that the precise immunological correlates of protection (CoP) against either infection with wild-type (wt) organisms or vaccines remain unknown, in part because ST and PA are human-restricted infections. The use of specimens from volunteers vaccinated and/or challenged with wt ST has begun to uncover immunological T cell-mediated immunity (T-CMI) effector mechanisms which might be associated with clinical outcome following challenge. No similar data is available for PA since the first wt PA challenge has just been performed. A critical gap also remains in our understanding of the mechanisms of antigen presentation for different Salmonella spp., which may underlie the development of effective adaptive T- CMI and B cell responses, as well as the immune responses elicited in the gut microenvironment following exposure to typhoidal and NTS infections. For these reasons, the overall goal of this application is to advance the development of vaccines against PA as well as broad-spectrum vaccines against enteric fevers, iNTS, and NTS, by identifying protective cross- reactive Salmonella spp. humoral, T effector, and regulatory immune responses, both systemically and in the gut microenvironment, and by defining the mechanisms of antigen presentation against ST, PA, iNTS and NTS that impact adaptive immune cell programming. To achieve these goals we will use PBMC from (i) a challenge study with wt PA with known clinical outcomes (e.g., non-disease or disease), (ii) a study with attenuated PA vaccine candidate strain CVD 1902 followed by challenge with wt PA, (iii) in vitro T cell priming systems and (iv) three human intestinal models: (a) bioengineered 3-D organoids, (b) enteroids, and (c) explants to perform the following Aims: Aim 1. Evaluate whether a defined set of B and T cellular responses in circulation are associated with protection from bacteremic infection and/or bacteremia-negative clinical disease (e.g., fever) following an oral challenge with wt PA in humans, and which regulatory mechanisms are involved in generating these responses. Aim 2. Evaluate whether interactions between ST, PA, iNTS and NTS and dendritic cells (DC) lead to the activation of diverse pathways which in turn determine the priming of defined T cell responses. Aim 3. Contrast molecular biomarker changes and function elicited in gut innate immune cells by various Salmonella serovars and the corresponding isogenic vaccine strains.
摘要(CETRRp5,Sztein,PL) 沙门氏菌感染。由于摄入了受污染的食物和水,包括伤寒 (主要由伤寒沙门氏菌(ST)和副伤寒沙门氏菌A(PA)引起),以及非伤寒(NTS)和侵袭性NTS 非传染性鼻炎(INTS)感染是世界许多地区的主要公共卫生问题,包括在美国 每年导致120万人患病。多药耐药(MDR)迅速增加,缺乏 针对PA、NTS或INT的疫苗为疫苗的开发增加了新的紧迫感 对抗这些病原体,最好是广谱疫苗。发展中的主要障碍之一 沙门氏菌疫苗。准确的免疫学相关保护(COP)是针对 感染野生型(Wt)生物或疫苗仍不清楚,部分原因是ST和PA 人类限制的感染。使用来自接种和/或挑战wt ST的志愿者的样本 已经开始揭示免疫T细胞介导的免疫(T-CMI)效应机制,这可能是 与挑战后的临床结果相关。自第一个wt PA以来,没有类似的数据可用 刚刚进行了挑战。在我们对这些机制的理解上也存在着严重的差距。 不同沙门氏菌的抗原提呈,这可能是发展有效的适应性T- CMI和B细胞反应,以及在下列肠道微环境中引发的免疫反应 暴露于伤寒和新城疫感染。 出于这些原因,这项应用的总体目标是推动疫苗的开发 PA以及针对肠道发热、INT和NTS的广谱疫苗,通过识别保护性交叉 反应性沙门氏菌。体液、T效应和调节性免疫反应,无论是系统性的还是在 肠道微环境,并通过确定针对ST、PA、INTS和NTS的抗原提呈机制 这会影响适应性免疫细胞编程。为了实现这些目标,我们将使用来自(I)挑战的PBMC 使用wt PA进行的已知临床结果的研究(例如,非疾病或疾病),(Ii)使用减弱的PA进行的研究 疫苗候选菌株CVD1902随后用wt PA攻击,(Iii)体外T细胞免疫系统和 (4)三种人体肠道模型:(A)生物工程3-D有机体,(B)肠样体,和(C)外植体 以下目标:目标1.评估循环中一组确定的B和T细胞反应是否 与预防菌血症感染和/或菌血症阴性的临床疾病(例如发烧)有关 在人类中口服wt PA后,哪些调节机制参与了 这些回应。目的2.评价ST、PA、INTS和NTS与树突状细胞之间的相互作用 (DC)导致不同途径的激活,而这些途径又决定了确定的T细胞反应的启动。 目的3.比较不同剂量不同药物对肠道天然免疫细胞分子标志物的影响及功能 沙门氏菌血清型和相应的同基因疫苗株。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Marcelo B. Sztein其他文献

Thymic physiology and biochemistry.
胸腺生理学和生物化学。
  • DOI:
  • 发表时间:
    1987
  • 期刊:
  • 影响因子:
    0
  • 作者:
    R. Schulof;Paul H. Naylor;Marcelo B. Sztein;Allan L. Goldstein
  • 通讯作者:
    Allan L. Goldstein
Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road
志贺菌疫苗的临床试验:在漫长而艰难的道路上前进两步后退一步
  • DOI:
    10.1038/nrmicro1662
  • 发表时间:
    2007-07-01
  • 期刊:
  • 影响因子:
    103.300
  • 作者:
    Myron M. Levine;Karen L. Kotloff;Eileen M. Barry;Marcela F. Pasetti;Marcelo B. Sztein
  • 通讯作者:
    Marcelo B. Sztein
The two-faced T cell epitope
双面T细胞表位
  • DOI:
  • 发表时间:
    2013
  • 期刊:
  • 影响因子:
    4.8
  • 作者:
    L. Moise;Andres H. Gutierrez;C. Bailey;Frances E Terry;Qibin Leng;Karim M. Abdel Hady;Nathan c. VerBerkmoes;Marcelo B. Sztein;P. Losikoff;William D. Martin;Alan Rothman;Anne Searls De Groot
  • 通讯作者:
    Anne Searls De Groot
Safety and immunogenicity in humans of enterotoxigenic Escherichia coli double mutant heat-labile toxin administered intradermally
皮内注射产肠毒素大肠埃希氏菌双突变不耐热肠毒素在人体中的安全性和免疫原性
  • DOI:
    10.1038/s41541-025-01071-7
  • 发表时间:
    2025-02-01
  • 期刊:
  • 影响因子:
    6.500
  • 作者:
    Marcela F. Pasetti;Patricia L. Milletich;Jessica A. White;Jessica Butts;Rebecca C. Brady;Michelle D. Dickey;Cassandra Ballou;Nicole Maier;Marcelo B. Sztein;Shahida Baqar;A. Louis Bourgeois;David I. Bernstein
  • 通讯作者:
    David I. Bernstein
Tu1886 – Commensal Derived Bioproducts Contribute to Modulate <em>S.</em> Typhi-Host Interaction
  • DOI:
    10.1016/s0016-5085(19)39869-5
  • 发表时间:
    2019-05-01
  • 期刊:
  • 影响因子:
  • 作者:
    Stefania Senger;Laura Ingano;Kourtney Nickerson;Marcelo B. Sztein;Alessio Fasano
  • 通讯作者:
    Alessio Fasano

Marcelo B. Sztein的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Marcelo B. Sztein', 18)}}的其他基金

Defining immunological mechanisms of serovar cross-reactivity to develop broad spectrum protective vaccines for typhoidal and non-typhoidal Salmonella infections in humans
定义血清型交叉反应的免疫学机制,以开发针对人类伤寒和非伤寒沙门氏菌感染的广谱保护性疫苗
  • 批准号:
    10364714
  • 财政年份:
    2019
  • 资助金额:
    $ 90.67万
  • 项目类别:
Broad spectrum vaccines to enteric fevers in humans: cross protective immunity
人类肠热病广谱疫苗:交叉保护性免疫
  • 批准号:
    8233359
  • 财政年份:
    2011
  • 资助金额:
    $ 90.67万
  • 项目类别:
Mucosal Immunity, Vaccines and Microbiota Interplay in Humans and Animal
人类和动物的粘膜免疫、疫苗和微生物群的相互作用
  • 批准号:
    8282922
  • 财政年份:
    2009
  • 资助金额:
    $ 90.67万
  • 项目类别:
Mucusal and Systemic Immunity, Vaccines and Microbiota Interplay in Humans
人类粘膜和系统免疫、疫苗和微生物群的相互作用
  • 批准号:
    8835015
  • 财政年份:
    2009
  • 资助金额:
    $ 90.67万
  • 项目类别:
Mucusal and Systemic Immunity, Vaccines and Microbiota Interplay in Humans
人类粘膜和系统免疫、疫苗和微生物群的相互作用
  • 批准号:
    8707660
  • 财政年份:
    2009
  • 资助金额:
    $ 90.67万
  • 项目类别:
Mucosal Immunity, Vaccines and Microbiota Interplay in Humans and Animal
人类和动物的粘膜免疫、疫苗和微生物群的相互作用
  • 批准号:
    8485521
  • 财政年份:
    2009
  • 资助金额:
    $ 90.67万
  • 项目类别:
Mucosal Immunity, Vaccines and Microbiota Interplay in Humans and Animal
人类和动物的粘膜免疫、疫苗和微生物群的相互作用
  • 批准号:
    8119519
  • 财政年份:
    2009
  • 资助金额:
    $ 90.67万
  • 项目类别:
Pilot Projects Research Core
试点项目研究核心
  • 批准号:
    7701569
  • 财政年份:
    2009
  • 资助金额:
    $ 90.67万
  • 项目类别:
A novel whole ORFeome approach to identify CD8+ T cell responses to S. Typhi prot
一种新颖的全 ORFeome 方法来识别 CD8 T 细胞对伤寒沙门氏菌 prot 的反应
  • 批准号:
    7701566
  • 财政年份:
    2009
  • 资助金额:
    $ 90.67万
  • 项目类别:
Administration Core
行政核心
  • 批准号:
    7701568
  • 财政年份:
    2009
  • 资助金额:
    $ 90.67万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 90.67万
  • 项目类别:
    Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 90.67万
  • 项目类别:
    Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 90.67万
  • 项目类别:
    Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 90.67万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 90.67万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 90.67万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 90.67万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 90.67万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 90.67万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 90.67万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了